Emergent BioSolutions
EBS
#6766
Rank
S$0.82 B
Marketcap
S$15.42
Share price
-1.24%
Change (1 day)
25.91%
Change (1 year)

Revenue for Emergent BioSolutions (EBS)

Revenue in 2025 (TTM): S$0.99 Billion

According to Emergent BioSolutions 's latest financial reports the company's current revenue (TTM ) is S$0.97 Billion. In 2024 the company made a revenue of S$1.37 Billion an increase over the revenue in the year 2023 that were of S$1.35 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Emergent BioSolutions from 2004 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) S$0.99 B-28.13%
2024 S$1.37 B1.97%
2023 S$1.35 B-6.63%
2022 S$1.44 B-35.46%
2021 S$2.24 B17.67%
2020 S$1.90 B43.7%
2019 S$1.32 B37.61%
2018 S$0.96 B46.89%
2017 S$0.65 B31.22%
2016 S$0.49 B-10.17%
2015 S$0.55 B24.14%
2014 S$0.44 B37.19%
2013 S$0.32 B57.07%
2012 S$0.20 B-41.24%
2011 S$0.35 B-3.95%
2010 S$0.36 B11.83%
2009 S$0.32 B29.08%
2008 S$0.25 B-2.99%
2007 S$0.26 B-0.75%
2006 S$0.26 B21.88%
2005 S$0.21 B59.75%
2004 S$0.13 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Merck
MRK
S$83.24 B 8,456.68%๐Ÿ‡บ๐Ÿ‡ธ USA
SIGA Technologies
SIGA
S$0.22 B-77.05%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
S$54.88 B 5,541.77%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
S$3.36 M-99.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$81.36 B 8,263.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$21.74 B 2,134.71%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Soligenix
SNGX
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA